Moderna rises 2.3% as firm starts COVID-19 vaccine trial in kids


Shares of Moderna went up 2.3% on Tuesday after the vaccine producer reported it had started its VOCID-19 vaccine trial in children aged between six months and 12 years old.

The vaccine trial will be highly indicative of the efficacy of Moderna’s developed COVId-19 immunization for kids. The vaccine, named mRNA-1273, will be given in two doses. Around 6,750 children from Canada and the United States are targeted to be subject to the study.

In America, Moderna’s COVID-19 vaccine has already been authorized for emergency use for people 18 years and above. Since the inoculation rollout, the vaccine was proven effective without many cases of major side effects reported. Moderna is already testing the shot in people ages between 12 and 18 years.

Another contributing factor to Moderna’s stock surge is the smooth and fast inoculation rollout in the United States.

The information and recommendations contained in this analytical document are published strictly for information purposes and are not considered as an offer to buy or sell the trading tools mentioned above and are not intended to motivate to perform certain transactions
Something went wrong